Understanding the Role of the Gut Microbiome in NAFLD
Posted 30th August 2019 by Liv Sewell
NAFLD is the primary contributor to chronic liver disease worldwide with incident rates of 20-30% in western countries and 5-18% in Asia. The discovery of early stage biomarkers for patients with the reversible form of the disease is therefore a research priority. Recent work has shown perturbation of the microbiome and specific microbiome-associated metabolites contribute to the phenotype of NAFLD.
A recap of the Microbiome & Probiotics Series: Europe
Posted 23rd August 2019 by Jane Williams
The Microbiome & Probiotics Series: Europe is one of the highlights of our calendar year. Kristin Neumann, author & founder of MyMicrobiome was one of our speakers on the cosmeceuticals track and was kind enough to write the following recap of the event, for people who weren’t able to attend this year. You can read the original article here.
Presentation slides from the 6th Microbiome R&D & Business Collaboration Forum
Posted 9th August 2019 by Jane Williams
Following the Microbiome R&D & Business Collaboration Forum, we have made the following presentation slides available from Finn Terge Hegge, Angela Sessitsch, Evelina Munukka and Jonathan de Jonge.
Increasing plant protein digestion in an in vitro model
Posted 19th July 2019 by Jane Williams
Population increases and patterns of consumption will put pressure on animal protein supply and price over the coming decades. Plant proteins are a viable alternative, but have a lower digestibility then animal proteins.
Microbiome R&D & Business Collaboration Forum presentation slides
Posted 15th July 2019 by Joshua Sewell
Following the Microbiome R&D & Business Collaboration Forum, we have made the following presentation slides from Karoline Faust, Dirk Hadrich, Lesley Hoyles & Jos Seegers available.
FMT-based discovery: from platform to product
Posted 5th July 2019 by Jane Williams
Fecal microbiota transplant (FMT) is probably the microbiome based therapy that has received the most media attention. It seems journalists love to talk about poo.
This has given momentum to research in the field. As the amount of trial data and fear of antibiotic resistance grows, FMT is now a much more common treatment for conditions like clostridioides difficile infection (CDI).
The Skin Microbiome & Cosmeceuticals Congress presentation slides
Posted 24th June 2019 by Joshua Sewell
Following the Skin Microbiome & Cosmeceuticals Congress: Europe, we have made the following presentation slides from Richard Andrews, Ingmar Claes, Marie Drago & Maya Ivanjesku available.
The top 4 challenges for microbiome companies – NIZO
Posted 8th May 2019 by Joshua Sewell
Microbiome research is abundant and profoundly inspiring. Whether focusing on cancer drug response, or the more classical field of gut discomfort solutions, we are clearly on the brink of some long-anticipated breakthroughs. But despite the promise, companies in the field face challenges.
